Conferences - Results from #240

ASCO GU 2023: Barriers to Guideline-Concordant Use of Bone Modifying Agents for Prostate Cancer February 16, 2023

ASCO GU 2023: Geographic Variation of Decipher® Genomic Classifier in Patients with Early Prostate Cancer February 16, 2023

ASCO GU 2023: Effect of Equal Access to Care on Prostate Cancer Progression in Minority Patients February 16, 2023

ASCO GU 2023: LuCAB: A Phase I/II Trial Evaluating Cabazitaxel in Combination with [177Lu]Lu-PSMA-617 in Patients with mCRPC February 16, 2023

ASCO GU 2023: Effect of Cerebral Dopamine Metabolism Genetic Polymorphism on Patient-Reported Quality-of-Life (QOL): An Analysis of the E3805 CHAARTED Trial February 16, 2023

ASCO GU 2023: The CONFIDENT-P Trial: Clinical Implementation of Artificial Intelligence Assistance in Prostate Cancer Pathology February 16, 2023

ASCO GU 2023: Efficacy and Safety of Darolutamide in Combination with ADT and Docetaxel by Disease Volume and Disease Risk in the Phase 3 ARASENS Study February 16, 2023

ASCO GU 2023: Phase III Study of Local or Systemic Therapy Intensification Directed by PET in Prostate Cancer Patients with Post-Prostatectomy Biochemical Recurrence (INDICATE): ECOG-ACRIN EA8191 February 16, 2023

ASCO GU 2023: Development and Validation of a Multi-Institutional Nomogram of Outcomes for PSMA-PET–based Salvage Radiotherapy in Recurrent Prostate Cancer February 16, 2023

ASCO GU 2023: Real World Prospective Evaluation of Clinical Outcomes in Patients with Non-Metastatic Castrate Resistant Prostate Cancer Treated with Darolutamide February 16, 2023

ASCO GU 2023: Baseline Characteristics Associated with PSA Progression-Free Survival in Patients (Pts) with High-Risk Biochemically Relapsed Prostate Cancer: Results from the Phase 3 PRESTO Study (AFT-19) February 16, 2023

ASCO GU 2023: Long-Term Safety and Tolerability of Darolutamide and Duration of Treatment in Patients with nmCRPC from the ARAMIS Rollover Study February 16, 2023

ASCO GU 2023: Geographic Variation in Utilization of Doublet Therapy for Metastatic Prostate Cancer February 16, 2023

ASCO GU 2023: Changes in Planned Disease Management after Piflufolastat F18 PET/CT in Men with Biochemically Recurrent Prostate Cancer and Low PSA Levels: A Secondary Analysis of Results from the CONDOR Study February 16, 2023

ASCO GU 2023: Discussion of Patient-Level Data Meta-Analysis of a Multi-Modal Artificial Intelligence Prognostic Biomarker and the FORMULA-509 Trial of Post-Operative Salvage Radiotherapy Post-Radical Prostatectomy February 16, 2023

ASCO GU 2023: A Phase II Trial Modifying Metabolic Syndrome and Cardiovascular Risk for Patients with Prostate Cancer on ADT Using a Risk Factor Modification Program and Continuous Fitbit Monitoring (ProTrio) February 16, 2023

ASCO GU 2023: EVOLUTION: Phase II Study of Radionuclide 177Lu-PSMA-617 Therapy Versus 177Lu-PSMA-617 in Combination with Ipilimumab and Nivolumab for Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC; ANZUP 2001) February 16, 2023

ASCO GU 2023: A Multi-Center, Prospective, Observational Study of Patients with Prostate Cancer Being Treated with Relugolix: OPTYX February 16, 2023

ASCO GU 2023: A phase II study of rucaparib monotherapy in nonmetastatic, hormone-sensitive prostate cancer (nmHSPC) with “BCRAness” genotype (ROAR) February 16, 2023

ASCO GU 2023: Increased Utilization of Prostate-Specific Membrane Antigen (PSMA)-Targeted Radionuclide Therapy (PSMA-TRT) in African American (AA) Patients at an Academic Medical Center February 16, 2023

Page 13 of 507